Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Opill (norgestrel) tablet for nonprescription use to prevent pregnancy the first daily oral contraceptive approved for use in the U.S. without a prescription.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Opill
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
U.S. Food and Drug Administration approved OTC, nicotine coated mint lozenges, works by reducing withdrawal symptoms in consumers who are trying to quit smoking.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Nicorette-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Opill (norgestrel) is a progestin-only daily oral contraceptive, available for over-the-counter (OTC) is used by females of reproductive potential to prevent pregnancy.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Opill
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Opill® is a progestin-only daily oral birth control pill (also referred to as a mini pill or non-estrogen pill), which prevents conception by suppressing ovulation.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Opill
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Acetaminophen and Ibuprofen acts by inhibiting cyclooxygenases (COX-1 and COX-2), and thus prostaglandins, which are produced by the body in response to injury and inflammation.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Product Name: Acetaminophen/Ibuprofen-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Opill® is a progestin-only daily birth control pill (also referred to as a mini pill or non-estrogen pill). If approved, Opill® would be the first ever daily birth control pill available OTC—without a prescription—in the U.S.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Opill
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.
Lead Product(s): Omeprazole Magnesium
Therapeutic Area: Gastroenterology Product Name: Omeprazole Magnesium-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
The approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg) to enter the OTC marketplace.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nasonex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).
Lead Product(s): Ulipristal Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ellaOne
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: HRA Pharma
Deal Size: Undisclosed Upfront Cash: $2,100.0 million
Deal Type: Acquisition September 08, 2021
Details:
Adapalene Cream indicated for the topical treatment of acne vulgaris in Perrigo Topical Generic Rx Business.
Lead Product(s): Adapalene
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Altaris Capital Partners
Deal Size: $1,550.0 million Upfront Cash: $1,500.0 million
Deal Type: Divestment March 01, 2021